PHAT - NASDAQ
Phathom Pharmaceuticals, Inc.
$10.09
+4.6%Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
At a Glance
Live SnapshotPhathom Pharmaceuticals, Inc. Management Team
Mr. Martin J. Gilligan
Chief Commercial Officer
Mr. Tom Harris
Chief Development Sciences Officer
Mr. Steven L. Basta M.B.A.
Chief Executive Officer, President & Director
Ms. Molly Henderson CPA, MBA
Chief Financial & Business Officer
Compensation
$777,763
Dr. Eckhard Leifke M.D., Ph.D.
Chief Medical Officer
Mr. Paul Cocja
Chief People Officer
Dr. Azmi Nabulsi M.D., M.P.H.
Co-Founder & Chief Operating Officer
Compensation
$888,897
Mr. David A. Socks
Co-Founder & Director
Compensation
$54,167
Mr. Jonathan Bentley
Senior Vice President & Head of Sales
Phathom Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have purchased $2.32M and sold $7K worth of PHAT shares, resulting in $2.31M of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
200.0K
2.32M
524
7.08K
+2.3M
+$2.31M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Narula Sanjeev
Officer: Chief Financial & Bus. Officer
$2.32M
Top Sellers
Breedlove Robert Charles
Officer: Principal Accounting Officer
$7K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $2.31M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Insider Participation
1 insider buyers and 1 sellers. Equal participation suggests mixed or neutral insider views.
SEC Filings
PHAT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 07, 2026 | May 19, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 23, 2025 | June 03, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 12, 2024 | May 23, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 13, 2023 | May 25, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 12, 2022 | May 25, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 06, 2021 | May 21, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 08, 2020 | May 21, 2020 | 2020 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.